Cencora hits 52-week low after guidance cut
Cencora (COR) shares dropped to a 52-week low following the company's decision to cut its full-year guidance. This reduction was primarily attributed to changes in its general merchandise business. The downward revision has raised concerns among investors regarding the company's future performance.
Globe Life Inc. $GL Shares Sold by Pzena Investment Management LLC
Pzena Investment Management LLC reduced its stake in Globe Life Inc. by 2.2% in the fourth quarter, though it still holds a significant position. Insiders, including the CEO and an EVP, also sold a substantial number of shares recently. Despite mixed quarterly results, analysts maintain a "Buy" rating for Globe Life with an average target price of $173.22, and the company announced a quarterly dividend of $0.33 per share.
Cencora Inc. stock (US15135B1017): guidance tweak and extra $2 billion buyback attract fresh attenti
Cencora Inc. has updated its fiscal year 2026 financial outlook, modestly raising its adjusted earnings guidance and authorizing an additional $2 billion for share repurchases. This comes amid an investor rights investigation by Pomerantz LLP. The company, a major pharmaceutical distributor, plays a critical role in the U.S. healthcare system, and its stock benefits from its stable business model and focus on specialty drugs, though it also faces regulatory and legal risks.
Cencora Raises Fiscal 2026 EPS Outlook, Authorizes $2 Billion Share Buyback
Cencora (COR) announced an increase in its long-term financial guidance for fiscal year 2026, raising its diluted earnings per share outlook from a range of $13.15 to $13.50 to a new range of $13.30 to $13.65. The company also authorized a new $2 billion share repurchase program, replacing its previous authorization. These strategic moves were highlighted in their annual Investor Day presentation.
Cencora raises FY26 EPS outlook, $2B buyback | COR Stock News
Cencora (NYSE: COR) has updated its fiscal year 2026 financial guidance, increasing its adjusted diluted earnings per share outlook to a range of $17.70 to $17.90 following opportunistic share repurchases in May. Additionally, the company's Board of Directors authorized a new $2.0 billion share repurchase program, reinforcing its commitment to returning value to shareholders. These actions align with Cencora's strategy to optimize market access for pharmaceutical innovators and deliver healthcare products.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
Pomerantz LLP is investigating potential securities fraud claims against Cencora, Inc. (NYSE: COR) on behalf of its investors. This investigation follows a significant drop in Cencora's stock price after the company released its second-quarter 2026 financial results, which missed revenue estimates and reduced full-year guidance due to "manufactured list price reductions." Investors who purchased Cencora securities are encouraged to contact Pomerantz LLP for more information.
Cencora stock (US15135B1017): transformation story after name change and solid earnings
Cencora, formerly AmerisourceBergen, is undergoing a strategic transformation with solid earnings and guidance, maintaining its position as a key pharmaceutical distributor. The company focuses on logistics, specialty pharmaceutical services, and manufacturer support, showing continued demand and strategic expansion into higher-value segments. Key factors for investors include its stable cash flows, capital-return policies, and sensitivity to US healthcare policy and regulatory changes.
Cencora stock (US15135B1017): transformation story after name change and solid earnings
Cencora, formerly AmerisourceBergen, is gaining investor attention following its rebranding and solid quarterly results, showcasing its position in the US drug supply chain. The company's fiscal Q2 2024 update reported higher revenue driven by specialty pharmaceuticals and strong US healthcare distribution, with reaffirmed full-year guidance. Cencora is strategically expanding internationally and focusing on higher-margin specialty services beyond traditional wholesale distribution.
Cencora stock (US15135B1017): Earnings miss and legal probe weigh on shares
Cencora shares are under pressure following a revenue miss and reduced full-year guidance reported on May 6, 2026. This resulted in a significant stock drop, further compounded by a securities investigation announced on May 18, 2026. Investors are now focused on the company's ability to demonstrate stable growth and restore confidence.
Cencora Inc. stock outperforms competitors on strong trading day
Shares of Cencora Inc. (COR) rose 1.64% to $266.17 on Tuesday, marking its second consecutive day of gains. This performance occurred during a generally negative trading session, as the S&P 500 Index (SPX) fell 0.67% and the Dow Jones Industrial Average (DJIA) dropped 0.65%.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Cencora, Inc. (COR) after the company missed Q2 2026 revenue estimates by $2.68 billion and reduced its full-year revenue growth guidance. Cencora's stock price fell 17.4% on May 6, 2026, following the announcement of a $2 billion revenue headwind from manufactured list price reductions. The firm encourages investors who purchased Cencora securities to assist in the investigation.
Cencora stock (US15135B1017): Q2 miss, legal probe and what matters now for investors
Cencora (US15135B1017) faced a Q2 2026 revenue miss, reduced guidance, and a significant stock drop, leading to a shareholder investigation. The company, a major pharmaceutical distributor, cited manufacturer list price reductions as a $2 billion revenue headwind. Investors are now focused on the persistence of pricing impacts, management's response to legal concerns, and Cencora's strategy within the evolving US drug distribution landscape.
Cencora hits 52-week low after guidance cut
Cencora (COR) shares dropped to a 52-week low after the company cut its full-year EPS guidance. The revised outlook includes anticipated lower contributions from its biocare services business due to slower-than-expected new patient starts for certain drugs and some program expirations. Despite this, Cencora affirmed its Q2 outlook, which remains within expectations.
Wellgistics Health Shares Jump 100% Ahead of Tuesday Earnings
Wellgistics Health's shares surged over 100% after the company withdrew preliminary proxy materials, signaling potential strategic deals and drawing investor attention ahead of its first-quarter earnings report on Tuesday. The Tampa-based firm is working to overhaul its capital structure and business, including a non-binding letter of intent to acquire WellCare Today for approximately $15 million, as it navigates Nasdaq's minimum bid requirements and liquidity concerns. The company faces stiff competition and challenges in its financial base, having reported a significant net loss in 2025.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Cencora, Inc. (COR) after the company missed Q2 2026 revenue estimates by $2.68 billion and reduced its full-year revenue growth guidance. Cencora's stock price fell significantly following the announcement, prompting the firm to encourage investors to connect for potential claims. The investigation focuses on Cencora's financial disclosures and the impact on its stock price.
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Cencora, Inc. (NYSE: COR) on behalf of investors for potential securities law violations. This follows Cencora's Q2 2026 financial results, which missed consensus estimates and led to a lowered full-year guidance, resulting in a 17.4% stock price drop. The firm encourages affected shareholders to join the fraud investigation.
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Cencora, Inc. (NYSE: COR) on behalf of investors for potential securities law violations. This investigation follows Cencora missing Q2 2026 consensus estimates, lowering full-year guidance, and a subsequent 17.4% drop in stock price due to reported "manufactured list price reductions" impacting revenue. Shareholders who suffered losses are encouraged to contact the firm.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) stock increased by 1.61% to $261.87 on a mixed trading day where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The company's stock closed 30.64% below its 52-week high of $377.54, which was reached on November 25th.
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Cencora, Inc. (NYSE: COR) on behalf of investors for potential securities law violations. This follows Cencora missing Q2 2026 consensus estimates, lowering its full-year guidance, and experiencing a 17.4% stock drop on May 6, 2026, due to a $2 billion revenue headwind from "manufactured list price reductions." Shareholders who incurred losses are encouraged to contact the firm to discuss their rights.
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating
Latitude Investment Management's Q4 2025 investor letter highlights Cencora (NYSE: COR) as a strong performer, driven by robust fundamentals and a strategic re-rating. The firm emphasizes its investment philosophy of focusing on a company's earnings power and attributes, noting Cencora's resilience as a drug distribution company and its essential role in the US healthcare system. While recognizing Cencora's potential, Latitude Investment Management also considers some AI stocks to have greater upside potential.
Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?
Cencora (COR) recently reported Q2 2026 results with higher sales and net income, but a revenue miss and lowered outlook, coupled with legal investigations, are challenging its margin-expansion narrative. The company aims to rebuild confidence by consistently meeting its 4-6% revenue growth guidance. Investors are now closely watching how Cencora manages drug price reduction impacts and defends its margins.
Cencora stock (US15135B1017): revenue miss, guidance tweak and share price pressure in focus
Cencora experienced a mixed fiscal Q1 2026, reporting a revenue miss despite slightly exceeding adjusted EPS expectations and maintaining stable margins. The company increased its full-year EPS guidance but its stock saw a 1.6% drop due to investor concerns over the revenue shortfall and ongoing pressures from biosimilar adoption and manufacturer price reductions. The article discusses Cencora's business model, industry trends, and competitive position within the US healthcare distribution landscape.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cencora, Inc. (NYSE: COR) following a significant drop in its stock price. This drop occurred after Cencora released Q2 2026 financial results that missed revenue estimates and reduced full-year guidance, largely due to "manufactured list price reductions." The firm encourages Cencora investors to connect to assist with the investigation, which is conducted on a contingency fee basis.
Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?
Cencora's recent fiscal Q2 2026 results showed increased sales and net income but a revenue miss, a lowered revenue outlook, and subsequent legal investigations have raised concerns. This article examines how these events impact the company's previously optimistic investment narrative focused on margin expansion and capital allocation. The key challenge now is for Cencora to rebuild investor confidence by consistently meeting its revised revenue growth guidance while defending its margins amidst ongoing pricing and regulatory pressures in the pharmaceutical supply chain.
Is It Time To Revisit Cencora (COR) After The Recent Share Price Slump?
Cencora (COR) has experienced a recent share price slump, but Simply Wall St's valuation checks indicate it is currently undervalued. Both a Discounted Cash Flow (DCF) analysis and a Price-to-Earnings (P/E) ratio comparison suggest the stock is undervalued, with the DCF model estimating its intrinsic value at $486.69 per share, significantly above its current price of approximately $257.71. The article encourages investors to analyze Cencora's narrative and future prospects further, considering a range of perspectives on its revenue and earnings growth.
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR
The Rosen Law Firm is investigating potential securities claims against Cencora, Inc. (NYSE: COR) on behalf of investors who may have suffered losses due to allegedly misleading business information. This investigation follows a Reuters article from May 6, 2026, which reported Cencora cut its revenue growth forecast after missing second-quarter estimates, causing its stock to fall 17.3%. The firm encourages affected investors to join the prospective class action to seek compensation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cencora, Inc. (COR) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Cencora, Inc. (COR) purchasers after the company missed Q2 2026 revenue estimates and lowered full-year revenue growth guidance, leading to a significant stock price drop. The firm encourages stockholders to connect to assist with the investigation. This comes after Cencora's stock fell 17.4% on May 6, 2026, following the announcement of a $2 billion revenue headwind due to manufactured list price reductions.
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cencora, Inc. (NYSE: COR) on behalf of investors who purchased the company's securities. This investigation follows Cencora's Q2 2026 financial results which missed revenue consensus estimates and led to a significant drop in its stock price. The firm encourages affected stockholders to contact them for more information regarding the investigation.
Cencora Inc. stock outperforms competitors despite losses on the day
Cencora Inc. (COR) shares slipped 1.07% to $257.71 on Friday, despite an overall poor trading session for the stock market, which saw the S&P 500 Index and Dow Jones Industrial Average decline more significantly. The company's stock closed 31.74% below its 52-week high achieved in November.
Cardinal Health Inc. stock (US14149Y1082): EPS beat contrasts with recent share-price weakness
Cardinal Health Inc. reported stronger-than-expected fiscal Q3 2026 earnings, topping consensus estimates and raising its full-year EPS guidance. Despite this positive financial performance and an improved technical signal with the stock climbing above its 200-day moving average, the company's shares have experienced recent weakness, lagging behind some healthcare peers. This divergence suggests investors are weighing fundamental improvements against market sentiment and the performance of other healthcare segments like managed care.
Wells Fargo Maintains Overweight Rating on Cencora (COR)
Wells Fargo maintained its Overweight rating on Cencora (COR) but lowered its price target to $331 from $429 due to disappointing U.S. healthcare earnings growth, though Cencora's core growth remained in line with peers. Citi also lowered its price target to $355. Cencora reported Q2 adjusted EPS of $4.75, slightly above estimates, while revenue of $78.4 billion missed expectations.
Cencora, Inc. Common Stock (NY: COR)
This article provides a list of recent news headlines related to Cencora, Inc. (NY: COR), formerly AmerisourceBergen. The news snippets cover topics such as promising chart action for Eli Lilly, McKesson, and Novartis, Cencora's Q4 FY23 earnings release, short interest analysis, and historical stock performance comparisons.
Cencora faces securities fraud probe after missing revenue targets and stock plunge.
Cencora Inc. is facing a securities fraud investigation by Pomerantz LLP after reporting disappointing Q2 2026 revenue of $78.3 billion, missing estimates by $2.68 billion, and subsequently lowering its full-year growth forecast. The company attributed a $2 billion revenue loss to price reductions, leading to a 17.4% drop in its stock price. Investors affected by the stock decline are encouraged to contact the law firm for potential class action participation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
Pomerantz LLP is investigating potential securities fraud claims against Cencora, Inc. (NYSE: COR) on behalf of its investors. This investigation follows a significant drop in Cencora's stock price after the company reported lower-than-expected Q2 2026 revenues, missing consensus estimates by $2.68 billion, and subsequently reduced its full-year revenue growth guidance. The firm encourages affected investors to contact them to learn more about joining a potential class action lawsuit.
Cardinal Health (CAH) Valuation Check As Income Drop And Goodwill Impairment Pressure The Story
Cardinal Health (CAH) is back in focus following a decline in net income and a significant goodwill impairment in its latest quarter, despite strong long-term shareholder returns and an increased dividend. The company's valuation is debated, with one narrative suggesting it is 24% undervalued at $245.27 per share, while its current P/E ratio of 28.1x is above the industry average, implying less margin of safety. Investors are urged to consider key rewards and warning signs to form their own view on the stock's future prospects.
10 Best Depressed Stocks to Buy in 2026
This article identifies O'Reilly Automotive, Inc. (NASDAQ: ORLY) as one of the best depressed stocks to buy in 2026, highlighting analyst upgrades and strong Q1 2026 performance. The company reported better-than-expected earnings and revenue, driven by robust comparable store sales in both professional and DIY segments. Analysts maintain positive outlooks, citing conservative guidance and market share expansion opportunities.
Cencora Inc. stock (US15135B1017): dividend date and legal probe in focus for investors
Cencora Inc. is under investor scrutiny due to its upcoming May 15 ex-dividend date providing a $0.60 per share payout, and an ongoing legal investigation by Pomerantz LLP following a 17% stock drop on May 6. The company, a major pharmaceutical distributor, maintains a strong dividend growth record and largely positive analyst ratings, despite the recent share price volatility and legal uncertainties. Investors are closely watching its financial performance and management's response to these developments.
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
Cardinal Health (CAH) stock has declined 9.4% year-to-date but has outperformed its industry and peers due to strong operational performance. Key growth drivers include specialty drug demand, the Red Oak Generics Program, and operational efficiency, leading to positive earnings estimate revisions. Despite a premium valuation and some potential normalization of growth drivers, analysts view CAH as a compelling investment due to its strong earnings trajectory and favorable industry trends, giving it a Zacks Rank #2 (Buy).
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. stock (COR) rose 2.12% to $261.11, outperforming the broader market during a strong trading session for the S&P 500 and Dow Jones Industrial Average. The company's shares closed 30.84% below its 52-week high reached on November 25th.
McKesson Is Down 26% From Its 52-Week High. It May Finally Be Time to Buy
McKesson (MCK) stock has dropped 26% from its 52-week high, presenting a potential buying opportunity. Despite a revenue miss, the company's profitability remains strong due to its fee-for-service model unaffected by WAC price declines and continued GLP-1 growth. Additionally, the strategic reshaping of its Medical-Surgical Solutions (MMS) business, including a $1.25 billion investment from Apollo Funds, de-risks its planned IPO and highlights undervalued assets.
ETFs Investing in Cencora, Inc. Stocks
This article lists various ETFs that invest in Cencora, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each fund. The purpose is to demonstrate how these ETFs can make investing in Cencora, Inc. more accessible and offer diversified opportunities with lower risk.
Are Wall Street Analysts Bullish on Cencora Stock?
Cencora (COR), a major pharmaceutical services company, has underperformed the broader market and industry ETFs over the past year. Despite a mixed Q2 2026 earnings report that saw revenues rise and adjusted EPS increase, shares plunged due to slowing earnings growth and a reduced full-year revenue outlook. Analysts currently have a "Strong Buy" consensus rating but have become slightly more bearish than two months prior, with a mean price target suggesting a significant upside from current market prices.
Cencora Inc. stock underperforms Wednesday when compared to competitors
Cencora Inc. (COR) stock fell 2.01% on Wednesday, closing at $255.68, even as the broader S&P 500 Index saw gains. The company's stock underperformed compared to its competitors, also trading significantly below its 52-week high.
Bronstein, Gewirtz & Grossman, LLC Encourages Cencora, Inc. (COR) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cencora, Inc. (NYSE: COR) on behalf of investors. This investigation follows Cencora's announcement of second-quarter 2026 financial results that missed consensus estimates and a reduction in full-year revenue growth guidance, which led to a significant drop in the company's stock price. The firm is encouraging Cencora investors who suffered losses to assist in the investigation.
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Cardinal Health's Pharmaceutical & Specialty Solutions segment is driving significant growth, with revenues climbing 19% and profit increasing 29% in Q3 fiscal 2026, primarily due to strong demand for specialty and branded products. The company anticipates specialty revenues to exceed $50 billion in fiscal 2026, supported by demographic trends and deepening partnerships. Competitors like McKesson and Cencora are also expanding their specialty segments, indicating a broader industry trend towards high-margin specialty pharmaceuticals.
Cencora (BIT:1COR) - Stock Analysis
This Simply Wall St analysis of Cencora (BIT:1COR) covers its valuation, future growth, past performance, financial health, dividends, management, and ownership. The report indicates Cencora is trading below its fair value with expected earnings growth and strong past performance, but notes a highly volatile share price and debt not well-covered by operating cash flow. Recent news highlights updated earnings guidance, quarterly dividend announcements, leadership changes, and significant acquisition activities.
Cencora stock (US15135B1017): Q2 earnings miss, analyst downgrades weigh on shares
Cencora reported Q2 fiscal 2026 results that missed analyst expectations, with revenue of $78.36 billion falling short of the $81.09 billion consensus. This miss triggered analyst downgrades, including Wells Fargo lowering its price target to $331 from $429. Despite these concerns, Morgan Stanley maintains a more constructive view, suggesting the selloff might be overdone given the broader healthcare distribution sector.
Cencora (NYSE:COR) Could Be A Buy For Its Upcoming Dividend
Cencora (NYSE:COR) is identified as a potential buy due to its upcoming dividend and strong financial indicators. The company boasts a 0.9% trailing dividend yield, a low payout ratio of 18% from profits and 29% from free cash flow, and impressive earnings per share growth of 31% over the past five years. This combination suggests a sustainable dividend and strong potential for long-term growth for shareholders.
Houston County receives state funding for industrial access work tied to Cencora expansion
Houston County has received state funding for industrial access work to support Cencora's expansion. This expansion will significantly increase Cencora's cold chain storage capacity, enhancing the area's ability to provide specialized medicines.
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Cencora, Inc. (COR) after the company announced disappointing financial results for Q2 2026, missing revenue estimates by $2.68 billion and reducing full-year 2026 revenue growth guidance. Cencora's stock subsequently fell by 17.4%. The law firm is encouraging investors who lost money to contact them to explore potential claims.
